Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ISRCTN38776134) titled 'A trial to evaluate the safety and efficacy of treatment with azacitidine in patients with symptomatic non-obstructive hypertrophic cardiomyopathy' on Feb. 3.
Study Type: Interventional
Study Design:
Allocation: Non-randomized controlled trial
Masking: Open (masking not used)
Control: Active
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: Belfast Health and Social Care Trust
Condition:
Symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)
Circulatory System
Intervention:
The investigational medicinal product (IMP) will be azacitidine. Azacitidine is an epigenetic-modifying therapy that irr...